Alzheimer disease therapy—moving from amyloid-β to tau
Alzheimer disease therapy—moving from amyloid-β to tau
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Notable failures of amyloid-β-targeted therapies in late-stage clinical trials for Alzheimer disease (AD) suggest the need for a reassessment of the amyloid cascade hypothesis of AD pathology. Here, Giacobini and Gold discuss the limitations of focusing on amyloid-β, and suggest a shift towards tau-directed therapy. They outline the rationale for s...
Alternative Titles
Full title
Alzheimer disease therapy—moving from amyloid-β to tau
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1566841950
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1566841950
Other Identifiers
ISSN
1759-4758
E-ISSN
1759-4766
DOI
10.1038/nrneurol.2013.223
